12
Views
3
CrossRef citations to date
0
Altmetric
ORIGINAL ARTICLE

Nuclear factor-κB regulates RANTES chemokine expression in response to tumor necrosis factor-α in fibroblast-like synoviocytes

, , , , &
Pages 37-43 | Received 29 Mar 2001, Accepted 21 Jul 2001, Published online: 02 Jan 2014

References

  • Harris ED Jr. Rheumatoid arthritis: pathophysiology and implica-tions for therapy. N Engl J Med 1990;322:1277–89.
  • Feldmann M, Brennan FM, Maini RN. Rheumatoid arthritis. Cell 1996;85:307–10.
  • Badolato R, Oppenheim JJ. Role of cytokines, acute-phase pro-teins, and chemokines in the progression of rheumatoid arthritis. Semin Arthritis Rheum 1996;26:526–38.
  • Burmester GR, Stuhlmuller B, Keyszer G, Kinne RW. Mono-nuclear phagocytes and rheumatoid synovitis. Arthritis Rheum 1997;40:5–18.
  • Kinne RW, Palombo-Kinne E, Emmrich F. T-cells in the patho-genesis of rheumatoid arthritis: villains or accomplices? Biochim Biophys Acta 1997;1360:109–41.
  • Berek C, Kim HJ. B-cell activation and development within chronically inflamed synovium in rheumatoid and reactive arthri-tis. Semin Immunol 1997;9:261–8.
  • Eigler A, Sinha B, Hartmann G, Endres S. Taming TNF: strategies to restrain this proinflammatory cytokine. Immunol Today 1997;18:487–92.
  • Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000;343:1594–602.
  • Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586–93.
  • Keffer J, Probert L, Cazlaris H, Georgopoulos S, Kaslaris E, Kioussis D, et al. Transgenic mice expressing human tumor necro-sis factor: a predictive genetic model of arthritis. EMBO J 1991;10:4025–4031.
  • Ward SG, Bacon K, Westwick J. Chemokines and T lymphocytes: more than an attraction. Immunity 1998;9:1–11.
  • Schall TJ, Bacon K, Toy KJ, Goeddel DV. Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES. Nature 1990;347:669–71.
  • Snowden N, Hajeer A, Thomson W, Oilier B. RANTES role in rheumatoid arthritis. Lancet 1994;343:547–8.
  • Ellingsen T, Buus A, Moller BK, Stengaard-Pedersen K. In vitro migration of mononuclear cells towards synovial fluid and plasma from rheumatoid arthritis patients correlates to RANTES synovial fluid levels and to clinical pain parameters. Scand J Ftheumatol 2000;29:216–21.
  • Boiardi L, Macchioni P, Meliconi R, Pulsatelli L, Facchini A, Salvarani C. Relationship between serum RANTES levels and radiological progression in rheumatoid arthritis patients treated with methotrexate. Clin Exp Ftheumatol 1999;17:419–25.
  • Barnes DA, Tse J, Kaufhold M, Owen M, Hesselgesser J, Strieter R, et al. Polyclonal antibody directed against human RANTES ameliorates disease in the Lewis rat adjuvant-induced arthritis model. J Clin Invest 1998;101:2910–9.
  • Rathanaswami P, Hachicha M, Sadick M, Schall TJ, McColl SR. Expression of the cytokine RANTES in human rheumatoid syn-ovial fibroblasts. Differential regulation of RANTES and interleukin-8 genes by inflammatory cytokines. J Biol Chem 1993;268: 29. 5834–9.
  • Nelson PJ, Kim HT, Manning WC, Goralski TJ, Krensky AM. Genomic organization and transcriptional regulation 30. of the FtANTES chemokine gene. J Immunol 1993;151: 2601–12.
  • Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Coo-per NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis 31. Rheum 1988;31: 315–24.
  • Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal 32. Biochem 1987;162: 156–9.
  • Maruyama N, Hirano F, Yoshikawa N, Migita K, Eguchi K, Tanaka H. Thrombin stimulates cell proliferation in human 33. fibroblast-like synoviocytes in nuclear factor-lcB activation and protein kinase C mediated pathway. J Ftheumatol 2000;27:2777–85.
  • Hirano F, Chung M, Tanaka H, Maruyama N, Makino I, Moore DD, et al. Alternative splicing variants of I1c1313 establish differen- 34. tial NF-IcB signal responsiveness in human cells. Mol Cell Biol 1998;18:2596–2607.
  • Suzuki N, Nakajima A, Yoshino S, Matsushima K, Yagita H, 35. Okumura K. Selective accumulation of CCR5 + T lymphocytes into inflamed joints of rheumatoid arthritis. Int Immunol 1999;11: 553–9.36.
  • Baeuerle PA, Baltimore D. NF-KB: ten years after. Cell 1996;87: 13–20.
  • Anderson DM, Maraskovsky E, Billingsley WL, Dougall WC, Tometsko ME, Roux ER, et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. 37. Nature 1997;390:175–9.
  • Bohuslav J, Kravchenko VV, Parry GC, Erlich JH, Gerondakis S, Mackman N, et al. Regulation of an essential innate immune re-sponse by the p50 subunit of NF-IcB. J Clin Invest 1998;102:1645-38. 52.
  • Sha WC. Regulation of immune responses by NF-IcB/Reel transcription factors. J Exp Med 1998;187:143-6.39.
  • Sen R, Baltimore D. Inducibility of lc immunoglobulin enhancer-binding protein NF-IcB by a posttranslational mechanism. Cell 1986;47:921–8.
  • Zabel U, Baeuerle PA. Purified human IlcB can rapidly dissociate the complex of the NF-KB transcription factor with its cognate DNA. Cell 1990;61:255–65.
  • Haskill S, Beg AA, Tompkins SM, Morris JS, Yurochko AD, Sampson-Johannes A, et al. Characterization of an immediate-early gene induced in adherent monocytes that encodes hcB-like activity. Cell 1991;65:1281–9.
  • Whiteside ST, Epinat JC, Rice NR, Israel A. IlcBs, a novel member of the IlcB family, controls RelA and cRel NF-IcB activity. EMBO J 1997;16:1413–26.
  • Wulczyn FG, Naumann M, Scheidereit C. Candidate proto-oncogene bc1-3 encodes a subunit-specific inhibitor of transcription factor NF-IcB. Nature 1992;358: 597–9.
  • Fujisawa K, Aono H, Hasunuma T, Yamamoto K, Mita S, Nishioka K. Activation of transcription factor NF-KB in human synovial cells in response to tumor necrosis factor ct. Arthritis Rheum 1996;39:197–203.
  • Suyang H, Phillips R, Douglas I, Ghosh S. Role of unphosphorylated, newly synthesized I1c1313 in persistent activation of NF-KB. Mol Cell Biol 1996;16:5444–9.
  • Johnson DR, Douglas I, Jahnke A, Ghosh S, Pober JS. A sustained reduction in I1c1313 may contribute to persistent NF-IcB activation in human endothelial cells. J Biol Chem 1996;271: 16317–22.
  • McKinsey TA, Brockman JA, Scherer DC, Al-Murrani SW, Green PL, Ballard DW. Inactivation of Ilc13(3 by the tax protein of human T-cell leukemia virus type 1: a potential mechanism for constitutive induction of NF-IcB. Mol Cell Biol 1996;16: 2083–90.
  • Velasco M, Diaz-Guerra MJ, Martin-Sanz P, Alvarez A, Bosca L. Rapid up-regulation of Ilc13(3 and abrogation of NF-IcB activity in peritoneal macrophages stimulated with lipopolysaccharide. J Biol Chem 1997;272:23025–30.
  • Aupperle KR, Bennett BL, Han Z, Boyle DL, Manning AM, Firestein GS. NF-IcB Regulation by IlcB kinase-2 in rheumatoid arthritis synoviocytes. J Immunol 2001;166:2705–11.
  • O'Connell MA, Bennett BL, Mercurio F, Manning AM, Mackman N. Role of IKK1 and IKK2 in lipopolysaccharide signaling in human monocytic cells. J Biol Chem 1998;273:30410–4.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.